Robert DeLuccia - Acurx Pharmaceuticals CoFounder Chairman
| ACXP Stock | USD 0.42 0.01 2.44% |
Insider
Robert DeLuccia is CoFounder Chairman of Acurx Pharmaceuticals LLC
| Age | 79 |
| Address | 259 Liberty Avenue, Staten Island, NY, United States, 10305 |
| Phone | 917 533 1469 |
| Web | https://www.acurxpharma.com |
Robert DeLuccia Latest Insider Activity
Tracking and analyzing the buying and selling activities of Robert DeLuccia against Acurx Pharmaceuticals stock is an integral part of due diligence when investing in Acurx Pharmaceuticals. Robert DeLuccia insider activity provides valuable insight into whether Acurx Pharmaceuticals is net buyers or sellers over its current business cycle. Note, Acurx Pharmaceuticals insiders must abide by specific rules, including filing SEC forms every time they buy or sell Acurx Pharmaceuticals'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Robert DeLuccia over a month ago Acquisition by Robert DeLuccia of 250000 shares of Acurx Pharmaceuticals at 0.7982 subject to Rule 16b-3 | ||
Robert DeLuccia over a month ago Acquisition by Robert DeLuccia of 250000 shares of Acurx Pharmaceuticals at 0.7982 subject to Rule 16b-3 | ||
Robert DeLuccia over three months ago Acquisition by Robert DeLuccia of 250000 shares of Acurx Pharmaceuticals at 3.15 subject to Rule 16b-3 | ||
Robert DeLuccia over six months ago Acquisition by Robert DeLuccia of 19737 shares of Acurx Pharmaceuticals at 3.8 subject to Rule 16b-3 |
Acurx Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (1.5634) % which means that it has lost $1.5634 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (4.9816) %, meaning that it created substantial loss on money invested by shareholders. Acurx Pharmaceuticals' management efficiency ratios could be used to measure how well Acurx Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of 03/21/2025, Return On Tangible Assets is likely to drop to -3.84. In addition to that, Return On Capital Employed is likely to drop to -2.95. At this time, Acurx Pharmaceuticals' Total Current Liabilities is relatively stable compared to the past year. As of 03/21/2025, Liabilities And Stockholders Equity is likely to grow to about 4.1 B, while Non Current Liabilities Total is likely to drop 0.00.Similar Executives
| Showing other executives | INSIDER Age | ||
| Kristina Masson | Acrivon Therapeutics, Common | 44 | |
| Rex CFA | Anebulo Pharmaceuticals | 64 | |
| MD MS | Candel Therapeutics | 53 | |
| Jesper Olsen | Acrivon Therapeutics, Common | N/A | |
| Eric Easom | AN2 Therapeutics | 57 | |
| Donna Dea | Aerovate Therapeutics | N/A | |
| Carrie Cox | Candel Therapeutics | 66 | |
| MBA MR | Aerovate Therapeutics | 62 | |
| MBA BS | AN2 Therapeutics | 49 | |
| David Mack | Pmv Pharmaceuticals | 63 | |
| George Eldridge | Aerovate Therapeutics | 62 | |
| Jason Amello | Candel Therapeutics | 56 | |
| Daniel Ryweck | Silo Pharma | 59 | |
| Josh Eizen | AN2 Therapeutics | N/A | |
| Erick MD | Acrivon Therapeutics, Common | 67 | |
| Timothy Pigot | Aerovate Therapeutics | 53 | |
| Kenneth Cundy | Anebulo Pharmaceuticals | 66 | |
| Inf MD | Candel Therapeutics | 64 | |
| Robyn Sweinhart | Rezolute | N/A | |
| Man MBA | Adagene | 48 | |
| Fangyong Du | Adagene | 54 | |
Management Performance
| Return On Equity | -4.98 | ||||
| Return On Asset | -1.56 |
Acurx Pharmaceuticals LLC Management Team
Elected by the shareholders, the Acurx Pharmaceuticals' board of directors comprises two types of representatives: Acurx Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Acurx. The board's role is to monitor Acurx Pharmaceuticals' management team and ensure that shareholders' interests are well served. Acurx Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Acurx Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| CPA CPA, CoFounder, Sec | ||
| Robert DeLuccia, CoFounder Chairman | ||
| CPA Esq, President CoFounder |
Acurx Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Acurx Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -4.98 | ||||
| Return On Asset | -1.56 | ||||
| Current Valuation | 5.41 M | ||||
| Shares Outstanding | 21.76 M | ||||
| Shares Owned By Insiders | 11.66 % | ||||
| Shares Owned By Institutions | 9.80 % | ||||
| Number Of Shares Shorted | 213.36 K | ||||
| Price To Book | 14.82 X | ||||
| EBITDA | (14.58 M) | ||||
| Net Income | (14.1 B) |
Pair Trading with Acurx Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Acurx Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Acurx Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving against Acurx Stock
| 0.87 | CMRX | Chimerix | PairCorr |
| 0.65 | CPIX | Cumberland Pharmaceuticals Downward Rally | PairCorr |
| 0.57 | FNA | Paragon 28 | PairCorr |
The ability to find closely correlated positions to Acurx Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Acurx Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Acurx Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Acurx Pharmaceuticals LLC to buy it.
The correlation of Acurx Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Acurx Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Acurx Pharmaceuticals LLC moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Acurx Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Acurx Stock Analysis
When running Acurx Pharmaceuticals' price analysis, check to measure Acurx Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Acurx Pharmaceuticals is operating at the current time. Most of Acurx Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Acurx Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Acurx Pharmaceuticals' price. Additionally, you may evaluate how the addition of Acurx Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.